MediWound Ltd. (MDWD), enzymatic therapeutics for tissue repair, on Tuesday announced it will host a virtual Key Opinion Leader (KOL) event on January 8, 2025, at 10:00 AM ET.
The event will focus on EscharEx, an innovative biologic drug in late-stage development for chronic wound debridement, specifically targeting Venous Leg Ulcers (VLUs).
The event will feature three distinguished clinical experts: Dr. John C. Lantis II, Dr. Vickie R. Driver, and Dr. Robert J. Snyder.
These experts will discuss promising Phase II results of EscharEx, its effectiveness in wound debridement, and the upcoming Phase III VALUE study in VLUs. They will also highlight EscharEx's competitive advantages and its unique commercial opportunity, addressing the substantial unmet need for better treatment options in chronic wound care.
In addition, MediWound will share details on the upcoming Phase II/III study focused on diabetic foot ulcers (DFUs).
The virtual event will include a live Q&A session with MediWound's leadership team, providing an opportunity for participants to engage with experts and ask questions.
MDWD closed Tuesday's (Dec. 17, 2024) trading at $17.27, up 3.10%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.